Monitor upcoming End-of-Phase 2 meeting with FDA for bamzireotide in NETs (targeted 1Q 2027) and further clinical data readouts for VMT01 and PSV359 in 2027. Cash runway into 2028 reduces near-term financing risk.
Drugs in focus
CATX drug pipeline →bamzireotide
◆ Mixed Named in this press release- Impact
- Phase
- Phase 1/2a
- Time to market
- At least 3-5 years, assuming a successful End-of-Phase 2 meeting in Q1 2027, a Phase 3 trial initiated in 2027, positive readout, and subsequent FDA filing and review.
- Next catalyst
- None dated
What to watchWatch for the End-of-Phase 2 meeting outcome with the FDA in Q1 2027, which will determine the Phase 3 trial design and registration path. Positive FDA alignment could re-rate the stock from its deeply depressed levels, while negative feedback or a delayed timeline would add to the execution risks flagged by RBC. The company's ~$100M market cap and likely need for financing to fund a Phase 3 trial create additional overhang.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $0.7864entry
- T+1 · 6d ago +4.93%α +3.62% · $0.8252
- T+4 · todayOpen
- T+5 · in 8h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Perspective Therapeutics reported a Q3 2026 net loss of $32.4M ($0.27 per share), wider than the $26.0M loss in Q3 2025, on minimal grant revenue of $20K. Cash and short-term investments rose to $202M, sufficient to fund operations into 2028. The press release highlights clinical progress across three radiopharmaceutical programs and a Fast Track designation for PSV359, but no revenue or EPS consensus beat/miss can be determined as the company is pre-revenue.
Key Financial Metrics
Key Facts
- Net loss of $32.4M ($0.27/share) for Q3 2026 vs $26.0M ($0.35/share) in Q3 2025
- Cash, cash equivalents, and short-term investments of $202M as of Sep 30, 2026, up from $145M at Dec 31, 2025
- R&D expenses $26.1M vs $20.3M year-over-year; G&A $8.3M vs $7.7M
- Grant revenue of $20K vs $209K in prior year quarter
- Phase 1/2a bamzireotide navoxetan (VMT-α-NET) data presented at ESMO and NANETS; Cohort 4 enrollment completed
- Lapemelanotide zapixetar (VMT01) monotherapy data in melanoma presented at SITC; 12 patients treated as of Oct 30, 2026
- PSV359 received FDA Fast Track Designation for FAP-positive solitary fibrous tumors in October 2026
- Clinical trial collaboration agreement with Merck to evaluate PSV359 in combination with Keytruda for certain lung and colorectal cancers
- Cash runway expected to fund planned clinical milestones and operations into 2028
Financial Impact
Net loss of $32.4M in Q3 2026; cash position of $202M provides runway into 2028
Risk Factors
- Pre-revenue stage with no approved products; continued operating losses
- Clinical trial risks across three early-stage programs
- Dependence on successful regulatory interactions and future financing
- Competition in radiopharmaceutical space
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3399027 |
Track record
34 reports on CATX
3 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +12.27% at T+5 after the Nov 5, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $0.9238 Now $0.9200 −0.41% settles Nov 18
- Nov 16, 2026today Insider Cluster Neutral 3/10 Entry $0.9652 Now $0.9200 −4.68% settles Nov 17
- Nov 12, 20264d ago SC 13D/A Bearish 6/10 Entry $0.9431 to $0.9238 Now $0.9200 +2.45% ▲ +2.05% +0.13% vs SPY
- Nov 10, 20266d ago SC 13G Neutral 2/10 Entry $0.7864 to $0.8252 Now $0.9200 +16.99% ▲ +4.93% +3.62% vs SPY
- Nov 9, 20267d ago 8-K Neutral 4/10 No price data
- Nov 9, 20267d ago Press Release Neutral 4/10 Viewing Entry $0.7864 to $0.8252 Now $0.9200 +16.99% ▲ +4.93% +3.62% vs SPY
- Nov 6, 202610d ago 8-K Neutral 4/10 Entry $0.8400 to $0.8556 Now $0.9200 +9.52% ▲ +1.86% −0.51% vs SPY
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $0.8400 to $0.8556 Now $0.9200 +9.52% ▲ +1.86% −0.51% vs SPY
- Nov 6, 202610d ago 8-K Neutral 4/10 Entry $0.8400 to $0.8556 Now $0.9200 +9.52% ▲ +1.86% −0.51% vs SPY
- Nov 5, 202611d ago Press Release Bullish 6/10 Entry $0.8400 to $0.8556 Now $0.9200 +9.52% ▲ +1.86% −0.51% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers